Invex Therapeutics Ltd (ASX:IXC)

Market Cap	8.64M +15.0%
Revenue (ttm)	46.83K -79.6%
Net Income	-1.35M
EPS	-0.02
Shares Out	75.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Open	0.1150
Previous Close	0.1150
Day's Range	0.1150 - 0.1150
52-Week Range	0.0900 - 0.1800
Beta	0.54
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About Invex Therapeutics

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IXC

Financial Performance

In fiscal year 2026, Invex Therapeutics's revenue was 46,826, a decrease of -79.56% compared to the previous year's 229,084. Losses were -1.35 million, 183.6% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error